Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Apical Flap Repositioning vs. Mucosa Excision With Free Gingival Grafts for Peri-Implant Keratinized Mucosa Augmentation (FGGIF)

15 agosto 2026 aggiornato da: Octavi Camps-Font, University of Barcelona

Multicenter Randomized Clinical Trial Comparing Apical Flap Repositioning Versus Vestibular Mucosa Excision Associated With Free Gingival Grafts for Peri-Implant Keratinized Mucosa Augmentation

The goal of this clinical trial is to learn which surgical technique works better to increase the amount of firm gum tissue (called keratinized mucosa) around dental implants in adults.

The main question it aims to answer is:

-Does repositioning the gum flap upward with stitches lead to a greater gain in firm gum tissue width at 6 months compared to simply removing the extra gum tissue, when both techniques are combined with a free gum graft?

Researchers will compare two techniques used during the second stage of implant surgery to see which one produces a greater gain in firm gum tissue around the implant.

Participants will:

  • Receive a free gum graft (a small piece of tissue taken from the roof of the mouth) placed around their dental implant during a routine surgical visit
  • Be randomly assigned to one of the two surgical techniques
  • Have digital scans of their mouth taken at 5 timepoints over 6 months
  • Complete a pain diary and answer questions about their experience during the first week after surgery
  • Attend follow-up visits at 6 weeks, 3 months, and 6 months after surgery

Panoramica dello studio

Descrizione dettagliata

This superiority multicenter randomized clinical trial is coordinated by the Universitat de Barcelona (UB) and includes the Universidad Complutense de Madrid (UCM) as a collaborating center.

Participant selection Adults with osseointegrated implants in the posterior maxilla or mandible presenting keratinized mucosa width of 2 mm or less and/or vestibular depth less than 4 mm will be screened for eligibility. Participants must be in periodontal and peri-implant health and have a plaque index of 15% or less.

Randomization Eligible participants will be randomly assigned (1:1) to one of two treatment groups using an Interactive Web Response System (IWRS) provided by Sealed Envelope Ltd. Randomization will take place intraoperatively, once the partial-thickness mucosal flap has been prepared.

Interventions

Group 1 (Control): Free gingival graft with apical repositioning and suturing of the vestibular mucosal flap to the periosteum Group 2 (Experimental): Free gingival graft with excision of the vestibular mucous tissue

Outcome assessment Soft tissue changes will be assessed at 5 timepoints (T0, Tim, T6w, T3m, T6m) using intraoral scans (TRIOS 3®, 3Shape) analyzed with Geomagic Control X® software through three-dimensional digital superimposition. Clinical measurements will also be performed using a calibrated periodontal probe and a customized thermoplastic stent to standardize the measurement point across visits.

Participants will complete a pain diary during the first 7 postoperative days recording pain intensity (100 mm visual analogue scale), analgesic consumption, and days with limited activity.

Sample size A total of 46 participants (23 per group) are required, accounting for a minimum clinically relevant difference of 1 mm in KTW gain, a standard deviation of 1.3 mm, 80% statistical power, 5% significance level, an intraclass correlation coefficient of 0.30 for multiple implants per patient, and a 15% dropout rate.

Statistical analysis The primary outcome will be analyzed in the intention-to-treat population using a generalized linear mixed model (GLMM), with patient as a random effect, adjusted for baseline KTW and study center.

Tipo di studio

Interventistico

Iscrizione (Stimato)

46

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Octavi Camps-Font, DDS MS PhD
  • Numero di telefono: +34 934 024 269
  • Email: ocamps@ub.edu

Backup dei contatti dello studio

Luoghi di studio

    • Barcelona
      • Barcelona, Barcelona, Spagna, 08907
        • Hospital Odontològic Universitat de Barcelona, L'Hospitalet de Llobregat,
        • Contatto:
          • Octavi Camps Font DDS MS PhD
          • Numero di telefono: +34 934 024 269
          • Email: ocamps@ub.edu

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Men or women aged 18 years or older who voluntarily agree to sign the informed consent form before any study-related procedure is performed.
  • Single or multiple edentulous spaces (≤3 units) located in the posterior maxilla or mandible, presenting osseointegrated implants in first-stage surgery with a -healing period of more than 8 weeks.
  • ASA classification I or II.
  • Periodontal and peri-implant health.
  • O'Leary plaque index ≤15%.
  • Keratinized mucosa width ≤2 mm and/or vestibular depth <4 mm at at least one site.
  • Commitment to attend all follow-up visits over 6 months.

Exclusion Criteria:

  • Systemic diseases that may interfere with performing FGG (free gingival graft), including but not limited to: poorly controlled diabetes mellitus (HbA1c > 8% or per clinical judgment), immunodeficiencies or immunosuppressive treatment, uncontrolled hematological diseases or coagulation disorders, anticoagulant or antiplatelet treatment that cannot be adjusted according to standard clinical practice, active neoplasms under treatment, severe renal or hepatic insufficiency, decompensated cardiovascular diseases, and any other medical condition that, in the investigator's judgment, could compromise participant safety or proper tissue healing.
  • Any contraindication to oral surgical procedures.
  • Periodontal and peri-implant health as defined by the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions.
  • Patients who smoke tobacco or equivalent products, as well as former smokers with an abstinence period ≤12 months.
  • History of substance abuse (drugs or alcohol) or any other factor (e.g., severe psychiatric illness) that, in the investigator's opinion, could interfere with the patient's ability to cooperate and comply with the study.
  • Patients who have participated in a clinical trial within the last 30 days.
  • Pregnant or breastfeeding women.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Apical Flap Repositioning
Free gingival graft with apical repositioning and suturing of the vestibular mucosal flap to the periosteum during second-stage implant surgery.
Autologous free gingival graft harvested from the palate and placed at the recipient site. The vestibular mucosal flap is repositioned apically and sutured to the periosteum during second-stage implant surgery.
Sperimentale: Vestibular Mucosa Excision
Free gingival graft with excision of the vestibular mucous tissue during second-stage implant surgery.
Autologous free gingival graft harvested from the palate and placed at the recipient site. The vestibular mucous tissue is excised during second-stage implant surgery.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Peri-implant keratinized tissue width (KTW) gain
Lasso di tempo: Baseline (T0) to 6 months (T6m)
Absolute change in KTW, measured digitally as the linear distance between the mucosal margin and the mucogingival junction on the vestibular aspect of the implant, using Geomagic Control X® software on intraoral scan models (TRIOS 3®, 3Shape).
Baseline (T0) to 6 months (T6m)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Clinical gain in peri-implant keratinized tissue width (KTW)
Lasso di tempo: Baseline (T0) to 6 months (T6m)
Absolute change in KTW, measured clinically with a calibrated periodontal probe using a customized thermoplastic stent.
Baseline (T0) to 6 months (T6m)
Change in graft height
Lasso di tempo: Immediate postoperative (Tim), 6 weeks (T6w), 3 months (T3m), 6 months (T6m)
Change in graft height, measured in millimeters (mm), between immediate postoperative and 6 months, assessed by 3D digital superimposition.
Immediate postoperative (Tim), 6 weeks (T6w), 3 months (T3m), 6 months (T6m)
Change in graft width
Lasso di tempo: Immediate postoperative (Tim), 6 weeks (T6w), 3 months (T3m), 6 months (T6m)
Change in graft width, measured in millimeters (mm), between immediate postoperative and 6 months, assessed by 3D digital superimposition.
Immediate postoperative (Tim), 6 weeks (T6w), 3 months (T3m), 6 months (T6m)
Graft area contraction
Lasso di tempo: Immediate postoperative (Tim) to 6 months (T6m)
Percentage of graft area reduction between immediate postoperative and 6 months, assessed by 3D digital superimposition.
Immediate postoperative (Tim) to 6 months (T6m)
Change in graft volume
Lasso di tempo: Immediate postoperative (Tim), 6 weeks (T6w), 3 months (T3m), 6 months (T6m)
Change in graft volume, measured in cubic millimeters (mm³), between immediate postoperative and 6 months, assessed by 3D digital superimposition.
Immediate postoperative (Tim), 6 weeks (T6w), 3 months (T3m), 6 months (T6m)
Vestibular depth
Lasso di tempo: Baseline (T0) to 6 months (T6m)
Change in vestibular depth from baseline to 6 months, assessed both digitally and clinically.
Baseline (T0) to 6 months (T6m)
Surgical time
Lasso di tempo: Intraoperative (Tim)
Time in minutes from anesthesia administration to placement of the last suture.
Intraoperative (Tim)
Adverse events
Lasso di tempo: Immediate postoperative (Tim) to 6 months (T6m)
Incidence and nature of postoperative adverse events related to the free gingival graft procedure.
Immediate postoperative (Tim) to 6 months (T6m)
Clinician-perceived surgical difficulty
Lasso di tempo: Intraoperative (Tim)
Degree of surgical difficulty perceived by the clinician at the end of the procedure, evaluated using a 100 mm visual analogue scale (0 = no difficulty, 100 = maximum imaginable difficulty).
Intraoperative (Tim)
Postoperative pain
Lasso di tempo: Up to 7 days postoperat
Pain intensity recorded at the end of the procedure and at 2, 6, 12 and 24 hours, and daily for 7 days, using a 100 mm visual analogue scale (0 = no pain, 100 = worst imaginable pain).
Up to 7 days postoperat
Analgesic consumption
Lasso di tempo: Up to 7 days postoperative
Number of doses of ibuprofen 600 mg and paracetamol 1 g consumed during the first 7 postoperative days.
Up to 7 days postoperative
Patient global satisfaction
Lasso di tempo: 7 days postoperative
Overall satisfaction with the intervention evaluated at 7 days postoperative using a 100 mm visual analogue scale (0 = completely dissatisfied, 100 = completely satisfied).
7 days postoperative
Days with limitation of daily activity
Lasso di tempo: Up to 7 days postoperative
Number of days with total or partial limitation of usual daily activity during the first 7 postoperative days.
Up to 7 days postoperative

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: Octavi Camps Font, University of Barcelona

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

30 settembre 2026

Completamento primario (Stimato)

30 settembre 2028

Completamento dello studio (Stimato)

30 marzo 2029

Date di iscrizione allo studio

Primo inviato

3 agosto 2026

Primo inviato che soddisfa i criteri di controllo qualità

15 agosto 2026

Primo Inserito (Effettivo)

19 agosto 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

19 agosto 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

15 agosto 2026

Ultimo verificato

1 agosto 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi